Life SciencesLiability
Get a quote

TL;DR

New York City runs a growing medical device and health-technology base anchored by major academic medical centers and hospital systems, with a strong digital-health and connected-device scene. Because so many NYC device companies are software-driven and data-handling, insurance programs here are built around products liability sized to device class, IDE clinical-trial coverage tied to the city's academic medical centers, GPO and hospital additional-insured requirements, and a cyber plus technology E&O layer that often becomes the primary product-liability vehicle for software as a medical device - with the New York SHIELD Act sitting above HIPAA as a state data-security layer.

New York City medical device

New York City medical device insurance - a software-driven, hospital-anchored device cluster.

New York City has built a growing medical device and health-technology base on the back of its major academic medical centers and hospital systems. The cluster skews toward software-driven and data-handling devices - connected diagnostics, monitoring platforms, and software as a medical device (SaMD) - developed close to the clinical institutions that both validate and buy them. That skew changes the shape of the insurance program: for many NYC device companies the software and the data are the product risk, not an accessory to it.

A New York City device program therefore cannot be a generic hardware-manufacturer placement. Products liability still has to be sized to the FDA device class the company operates in, but the connected and data-handling nature of the portfolio pulls cyber and technology errors and omissions to the front of the tower, and the hospital purchase and group purchasing organization (GPO) contracts common in the city attach insurance schedules a standard placement does not anticipate. The program has to answer the device class, the clinical-trial exposure, the contractual insurance requirements, and the data-security layer at the same time.

Get a quoteRun the Free Analyzer

Last updated 2026-07-14

Cluster shape

A hospital-anchored cluster with a digital-health skew.

The city's academic medical centers and large hospital systems are the gravitational center of the cluster - they run the clinical studies that validate new devices, they employ the clinician-founders who spin companies out, and they are the purchasers whose contracts dictate insurance terms. Device operators cluster around that clinical core rather than around a single manufacturing corridor, so the load-bearing exposures are clinical-trial and contractual rather than heavy-industrial.

A large share of NYC device companies are software-driven and data-handling. Connected devices, remote-monitoring platforms, diagnostic software, and SaMD dominate the pipeline, which means the product is frequently code and patient data rather than a physical instrument. For these operators the primary product-liability trigger can sit inside a technology E&O or cyber form rather than a traditional products form, and the data-security obligations are as material as the bodily-injury exposure.

Because the cluster is anchored to hospitals and health systems, nearly every commercial relationship runs through a purchase contract or a GPO supplier agreement. Those agreements - not New York device demand in the abstract - are what set the insurance requirements the operator has to satisfy, which makes contract review a central part of building a NYC device program.

Coverage architecture

Coverage built for device class, connectivity, and hospital contracts.

Products liability is sized to the FDA device class the company operates in - Class I, Class II, or Class III. Higher-class and implantable or life-sustaining devices carry materially greater severity and demand larger towers and tighter contractual terms than a low-risk Class I product, so the tower is scoped to the class and indication rather than to a flat market default. IDE clinical-trial coverage is layered in for companies running investigational studies through the city's academic medical centers, sized to the trial design and the institutional agreements.

Hospital purchase contracts and GPO supplier agreements - Vizient, Premier, and HealthTrust among them - typically require the buyer and the GPO be named as additional insured for both products AND completed operations, on a primary and non-contributory basis, at specified limits. A blanket additional-insured endorsement that excludes products and completed operations is a common and serious gap, because it silently fails the exact requirement these contracts impose. Product recall is carried as a separate first-party trigger, since a recall is a direct balance-sheet event distinct from third-party bodily-injury liability.

For the software-driven and connected devices that dominate the NYC cluster, cyber and technology E&O frequently become the primary product-liability vehicle - the SaMD malfunction, the algorithm error, and the data breach are the loss events, and a traditional products form alone leaves them uncovered. The data-security program has to be built to answer the New York SHIELD Act alongside HIPAA, so that state and federal obligations are both satisfied rather than assuming HIPAA compliance covers the state layer.

Regulatory + market context

New York context and the device data-security layer.

Medical devices are regulated federally by the FDA under the device framework, with the Class I, Class II, and Class III risk tiers and the investigational device exemption (IDE) pathway driving the core products and clinical-trial underwriting. That federal classification, not New York law, sets the products-liability architecture - which is why a NYC device program is underwritten around device class and indication first and location second.

Where New York adds a distinct layer is data security. The New York SHIELD Act imposes state data-security and breach-notification obligations that sit above HIPAA for the connected and data-handling devices common in the city, so a device company handling patient data has to satisfy the state regime in addition to the federal one. For a software-driven NYC device operator, the cyber and technology E&O placement should be structured to respond to SHIELD Act and HIPAA exposure together rather than treating HIPAA compliance as sufficient.

Frequently asked

Common questions from New York City medical device operators

What makes New York City medical device insurance distinct?

The NYC device cluster skews heavily toward software-driven and connected, data-handling devices developed around the city's academic medical centers - SaMD, remote monitoring, and diagnostic software rather than pure hardware. That skew pulls cyber and technology E&O to the front of the program as a primary product-liability vehicle, and layers the New York SHIELD Act on top of HIPAA as a data-security obligation. A generic hardware-manufacturer placement under-sizes the software, data, and state-law exposure that defines this market.

How is a device products liability tower sized in New York City?

The tower is scoped to the FDA device class - Class I, Class II, or Class III. A low-risk Class I product carries far less severity than a Class II diagnostic or a Class III implantable or life-sustaining device, so limits scale with the class, the indication, and whatever the hospital and GPO contracts specify. The class drives the products architecture, and the buyer contracts frequently set the minimum limits the operator has to carry.

What do hospital and GPO contracts require from a NYC device company?

Hospital purchase contracts and GPO supplier agreements - Vizient, Premier, and HealthTrust - typically require the buyer and the GPO be named as additional insured for both products AND completed operations, on a primary and non-contributory basis, at specified limits. The common failure is a blanket additional-insured endorsement that excludes products and completed operations, which silently fails the contract. Product recall is usually carried separately as a first-party trigger.

How are software and SaMD devices covered, and why does the NY SHIELD Act matter?

For the connected and software-driven devices common in NYC, cyber and technology E&O frequently become the primary product-liability vehicle - a SaMD algorithm error, malfunction, or data breach is the loss event, and a traditional products form alone can leave it uncovered. The New York SHIELD Act adds a state data-security and breach-notification layer above HIPAA for data-handling devices, so the program should be built to respond to both the SHIELD Act and HIPAA rather than assuming HIPAA compliance covers the state obligation.

Medical device insurance practice →Device products liability →NYC biotech insurance →New York state guide →

Free coverage review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.

Get my quote

Specifically for New York City medical device operators.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.